MetaADEDB 2.0 @ LMMD
Flavoxate
(SPIUTQOUKAMGCX-UHFFFAOYSA-N)
Structure
SMILES
O=C(c1cccc2c1oc(c1ccccc1)c(c2=O)C)OCCN1CCCCC1
Type(s)
Approved
ATC code(s)
G04BD02
Molecular Formula:
C24H25NO4
Molecular Weight:
391.460
Log P:
4.3490
Hydrogen Bond Acceptor:
5
Hydrogen Bond Donor:
0
TPSA:
59.75
CAS Number(s):
3717-88-2; 15301-69-6
Synonym(s)
1.
Flavoxate
2.
Bladuril
3.
Flavoxate Hydrochloride
4.
Spasuret
5.
Urispas
6.
Uronid
7.
Hydrochloride, Flavoxate
External Link(s)
MeSHD005422
PubChem Compound3354
ChEBI5088
CHEMBLCHEMBL1493
DrugBankDB01148
DrugCentral1175
IUPHAR/BPS Guide to PHARMACOLOGY7187
KEGGcpd:C07809
dr:D07961
Therapeutic Target DatabaseD0ND2J
ZINC608382
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Unevaluable eventFAERS: 1OFFSIDES
US FAERS
2Abdominal PainOFFSIDES
3Acid refluxOFFSIDES
4Acute Coronary SyndromeOFFSIDES
5AdenomaOFFSIDES
6AgraphiaOFFSIDES
7Alanine Aminotransferase IncreasedOFFSIDES
8AneurysmOFFSIDES
9AnorexiaOFFSIDES
10AnosmiaOFFSIDES
11Anticonvulsant drug level decreasedOFFSIDES
12AscitesOFFSIDES
13AstheniaOFFSIDES
14Asymptomatic bacteriuriaOFFSIDES
15Atrial tachycardiaOFFSIDES
16AuraOFFSIDES
17BedriddenOFFSIDES
18Biliary dilatationOFFSIDES
19Blood GlucoseOFFSIDES
20Blood albumin decreasedOFFSIDES
21Blood alkaline phosphatase increasedOFFSIDES
22Blood creatine phosphokinase increasedOFFSIDES
23Blood creatinine increasedOFFSIDES
24Blood lactate dehydrogenase increasedOFFSIDES
25Blood sodiumOFFSIDES
26Blood urea increasedOFFSIDES
27Burning sensationOFFSIDES
28Cardioactive drug levelOFFSIDES
29Catheter related complicationOFFSIDES
30CellulitisOFFSIDES
31Chest wall painOFFSIDES
32CholangiolitisOFFSIDES
33ChromaturiaOFFSIDES
34Completed SuicideOFFSIDES
35DehydrationOFFSIDES
36Depressed Level of ConsciousnessOFFSIDES
37DrowsinessSIDER
38DuodenitisOFFSIDES
39Ear congestionOFFSIDES
40Electrocardiogram ST-T segment abnormalOFFSIDES
41EosinophiliaSIDER
42ErythromelalgiaOFFSIDES
43Escherichia infectionOFFSIDES
44Feeling abnormalSIDER
45Gamma-Glutamyltransferase IncreasedOFFSIDES
46HeadacheSIDER
47Hepatic cancer metastaticOFFSIDES
48HydronephrosisOFFSIDES
49HyperpyrexiaSIDER
50Immune reconstitution syndromeOFFSIDES
51IncontinenceOFFSIDES
52Infusion site mobility decreasedOFFSIDES
53Intestinal ObstructionOFFSIDES
54Kidney FailureOFFSIDES
55LeukopeniaSIDER
56LipaseOFFSIDES
57Malignant neoplasm progressionOFFSIDES
58Mental status changesOFFSIDES
59Metabolic acidosisOFFSIDES
60Multiple sclerosis relapseOFFSIDES
61Musculoskeletal stiffnessOFFSIDES
62Myocardial Infarction18378025CTD
63Myoglobin urine presentOFFSIDES
64NauseaSIDER
65NephrolithiasisOFFSIDES
66NervousnessSIDER
67Neuroleptic Malignant SyndromeOFFSIDES
68Nocturia18411771CTD
OFFSIDES
69OliguriaOFFSIDES
70Optic NeuritisOFFSIDES
71Other dermatosesSIDER
72PalpitationsSIDER
73Personality ChangeOFFSIDES
74Pharyngolaryngeal PainOFFSIDES
75PolyuriaOFFSIDES
76Portal HypertensionOFFSIDES
77Post procedural complicationOFFSIDES
78Postoperative infectionOFFSIDES
79Productive CoughOFFSIDES
80Prostatic Hyperplasia18411771CTD
81PyelonephritisOFFSIDES
82Respiratory FailureOFFSIDES
83SinusitisOFFSIDES
84SomnolenceSIDER
85Sudden onset of sleepOFFSIDES
86TachycardiaSIDER
87TensionSIDER
88TinnitusOFFSIDES
89UrticariaSIDER
90VertigoSIDER
91VomitingSIDER
92Wound infection pseudomonasOFFSIDES
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120240

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.